Vimarsana
Biggest News Aggregation in the World

Digihaler System News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Digihaler System. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Digihaler System Today - Breaking & Trending Today

Teva's Digital Health Collaboration with Rimidi Expands to Include Respiratory Monitoring Program Integration with a Large U.S. Health System - Vimarsana News

Teva's Digital Health Collaboration with Rimidi Expands to Include Respiratory Monitoring Program Integration with a Large U.S. Health System

California’s Desert Oasis Healthcare implements Rimidi’s Respiratory Module for respiratory patient monitoring, based on data collected by Teva’s Digihaler®... | March 27, 2023

Desert Oasis Healthcare Partners with Rimidi to Help Improve Asthma Management for Patients using Teva Digihaler® Technology - Vimarsana News

Desert Oasis Healthcare Partners with Rimidi to Help Improve Asthma Management for Patients using Teva Digihaler® Technology

Atlanta (PRWEB) March 21, 2023 -- Rimidi, a leading clinical management platform designed to optimize clinical workflows, enhance patient experiences and

Source: prweb.com
Teva to Present New Data from CONNECT2 Study on its Digihaler System at the American Academy of Allergy, Asthma and Immunology (AAAAI) 2023 Annual Meeting - Vimarsana News

Teva to Present New Data from CONNECT2 Study on its Digihaler System at the American Academy of Allergy, Asthma and Immunology (AAAAI) 2023 Annual Meeting

24.02.2023 - Teva Pharmaceuticals USA, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that new data on its Digihaler System will be presented at the American Academy of Allergy, Asthma and Immunology (AAAAI) ... Seite 1

Teva to Present Latest Research from the CONNECT1 and CONNECT2 Clinical Trials at the American Colle - Vimarsana News

Teva to Present Latest Research from the CONNECT1 and CONNECT2 Clinical Trials at the American Colle

Findings from the first clinical trial program comparing the use of Teva’s Digihaler® System to standard of care in asthma management will be presented across six abstractsTEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals USA, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NY...

Teva Pharmaceutical Industries Limited: Teva to Present First Data Set from the CONNECT1 Clinical Trial on ProAir Digihaler (albuterol sulfate) Inhalation Powder at the European Respiratory Society (ERS) International Congress 2022 - Vimarsana News

Teva Pharmaceutical Industries Limited: Teva to Present First Data Set from the CONNECT1 Clinical Trial on ProAir Digihaler (albuterol sulfate) Inhalation Powder at the European Respiratory Society (ERS) International Congress 2022

The study evaluated the effect of the ProAir Digihaler System on asthma control versus standard of care as measured by the Asthma Control Test, and explored use of the ProAir Digihaler System to help